Pharmaceutical giant GSK and the University of Oxford are collaborating on developing a cancer vaccine that aims to detect ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GSK and Oxford researchers to create cancer vaccine to stop disease developing - GSK will invest up to £50 million in the new ...

Scientists at Oxford University, which pioneered Covid-19 vaccines, turn attention to ‘detecting the undetectable’ and ...

GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...

A programme looking to advance the understanding of how cancer develops has been backed with £50 million. Global biopharma company GSK has invested up to £50 million in a collaboration with Oxford ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

A new cancer vaccine is being created to analyse how pre-cancerous cells develop to target the disease before it takes hold.

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer ...

GSK plc and the University of Oxford (Oxford) announced that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination. The GSK-Oxford Cancer ...